NOSMOK nicotine lozenges will help people in reducing their urge to consume or smoke tobacco and relieve the psychological and psychomotor withdrawal symptoms and help them in their tobacco-cessation journey
J B Chemicals and Pharmaceuticals has launched NOSMOK – prescription-medicated nicotine lozenges as part of a 360 degrees tobacco-cessation initiative on World No Tobacco Day. NOSMOK nicotine lozenges will help people in reducing their urge to consume or smoke tobacco and relieve the psychological and psychomotor withdrawal symptoms and help them in their tobacco cessation journey, the company said in a statement.
It also said that the medicated nicotine lozenges will be available in mint flavour as sugar-based and sugar-free variants in 2mg and 4mg strengths. These lozenges are a part of the global JBCPL portfolio which are being introduced in India.
On this occasion, an AI-enabled Chatbot – Dr Will – has also been launched to encourage and support tobacco smokers to quit smoking and improve their quality of life.
Dr Will is a comprehensive digital programme that will help smokers in understanding their smoking triggers and motivate them to succeed in quitting. It will also support doctors in counselling smokers to quit the habit,” added the statement.
It further said that the chatbot is designed as a support mechanism and a helping hand to aid in the journey of tobacco cessation. It will answer patient queries related to quitting smoking options, make relevant information and support available to its users.
Talking about how challenging quitting tobacco is, Nikhil Chopra, CEO and Whole Time Director, JB Chemicals and Pharmaceuticals, said, “India’s death burden and the economic costs from tobacco usage are unacceptably high and it is critical that we address this issue. Studies indicate that over 55 per cent of tobacco users are willing to quit all forms of tobacco. However, quitting tobacco is a challenge, especially with the added social and economic stresses because of the pandemic. Our study of the market led us to realise that a successful tobacco-cessation initiative would require not just nicotine-replacement therapy, but also patient education and support through the journey to quit smoking. This has led to our launching nicotine replacement pharmacotherapy, NOSMOK, accompanied by a digital AI-enabled WhatsApp-based chatbot, DrWill. We are confident that these will help tobacco users and smokers to successfully beat their habit and emerge tobacco free.”
- Advertisement -